Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Carbidopa
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to the effect of three single oral doses of nebicapone (50 mg,
100 mg and 200 mg) on the levodopa pharmacokinetics when administered in combination with a
single-dose of controlled release levodopa 200 mg/carbidopa 50 mg (Sinemet CR 200/50).
Phase:
Phase 1
Details
Lead Sponsor:
Bial - Portela C S.A.
Treatments:
Carbidopa Carbidopa, levodopa drug combination Levodopa